



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Angeline Ingrid Bartholomeusz, et al. **Examiner:** Unassigned

**Serial No.:** 10/576,906 **Art Unit:** Unassigned

**Filed:** April 21, 2006 **Docket:** 19781

**For:** HBV VARIANTS DETECTION  
AND APPLICATION **Dated:** October 19, 2006

Mail Stop PCT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. PCT International Publication No. WO 03/087351 A1, published October 23, 2003;
2. PCT International Publication No. WO 03/066841, published August 14, 2003;
3. PCT International Publication No. WO 2004/031224 A2, published April 15, 2004;
4. PCT International Publication No. WO 00/61758, published October 19, 2000;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 19, 2006



Xiaochun Zhu

5. Torresi J. et al., "Restoration of Replication Phenotype of Lamivudine-Resistant Hepatitis B Virus Mutants by Compensatory Changes in the "Fingers" Subdomain of the Viral Polymerase Selected as a Consequence of Mutations in the Overlapping S Gene", *Virology*, 299:88-99 (2002); and
6. Ono S.K. et al., "The Polymerase L528M Mutation Cooperates with Nucleotide Binding-Site Mutations, Increasing Hepatitis B Virus Replication and Drug Resistance", *The Journal of Clinical Investigation*, 107(4):449-455 (2001).

The references were cited in an International Search Report dated December 20, 2004 received from the Australian Patent Office. Applicants are submitting copies of the above-cited references. A copy of the International Search Report was previously submitted by Applicants on April 21, 2006. The relevance of the above-identified references has been described in the International Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

XZ:dg

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

19781

Application Number

10/576,906

Applicant(s)


Angeline Ingrid Bartholomeusz, et al.

Filing Date

April 21, 2006

Group Art Unit

Unassigned



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 03/087351 A1	10/23/03	PCT			✓	
		WO 03/066841	8/14/03	PCT			✓	
		WO 2004/031224 A2	4/15/04	PCT			✓	
		WO 00/61758	10/19/00	PCT			✓	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Torresi J. et al., "Restoration of Replication Phenotype of Lamivudine-Resistant Hepatitis B Virus Mutants by Compensatory Changes in the "Fingers" Subdomain of the Viral Polymerase Selected as a Consequence of Mutations in the Overlapping S Gene", Virology, 299:88-99 (2002)
		Ono S.K. et al., "The Polymerase L528M Mutation Cooperates with Nucleotide Binding-Site Mutations, Increasing Hepatitis B Virus Replication and Drug Resistance", The Journal of Clinical Investigation, 107(4):449-455 (2001)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1645  
1/14

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> <b>(Under 37 CFR 1.97(b) or 1.97(c))</b>		Docket No. 19781
--	--	---------------------

In Re Application Of: **Angeline Ingrid Bartholomeusz, et al.**

OCT 23 2006

Examiner

Unassigned

Customer No.

23389

Group Art Unit

Unassigned

Confirmation No.

Unassigned

Title:

**HBV VARIANTS DETECTION AND APPLICATION**

Address to:

**Commissioner for Patents**  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

**OR**

the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
19781

In Re Application of: **Angeline Ingrid Bartholomeusz, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/576,906	April 21, 2006	Unassigned	23389	Unassigned	Unassigned

Title:  
**HBV VARIANTS DETECTION AND APPLICATION**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of \_\_\_\_\_ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

Charge the amount of \_\_\_\_\_  
 Credit any overpayment.  
 Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 19, 2006

  
(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

Dated: **October 19, 2006**

**Xiaochun Zhu**  
Registration No. 56,311  
Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
516-742-4343

CC: